Masimo Corporation (MASI) Shares Sold by First Trust Advisors LP
First Trust Advisors LP lowered its position in shares of Masimo Corporation (NASDAQ:MASI) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,965 shares of the medical equipment provider’s stock after selling 9,806 shares during the period. First Trust Advisors LP owned 0.12% of Masimo Corporation worth $5,376,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Masimo Corporation by 4,676.3% in the first quarter. BlackRock Inc. now owns 7,364,235 shares of the medical equipment provider’s stock worth $686,789,000 after buying an additional 7,210,051 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Masimo Corporation by 5.9% in the first quarter. Vanguard Group Inc. now owns 4,617,633 shares of the medical equipment provider’s stock worth $430,641,000 after buying an additional 258,719 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Masimo Corporation by 28.0% in the second quarter. Acadian Asset Management LLC now owns 1,791,597 shares of the medical equipment provider’s stock worth $163,356,000 after buying an additional 392,410 shares during the last quarter. State Street Corp boosted its stake in shares of Masimo Corporation by 42.8% in the first quarter. State Street Corp now owns 1,401,516 shares of the medical equipment provider’s stock worth $130,704,000 after buying an additional 419,767 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Masimo Corporation by 36.9% in the first quarter. Geode Capital Management LLC now owns 645,254 shares of the medical equipment provider’s stock worth $60,175,000 after buying an additional 173,931 shares during the last quarter. Institutional investors and hedge funds own 83.27% of the company’s stock.
Masimo Corporation (NASDAQ MASI) opened at 84.38 on Friday. The company has a 50-day moving average of $89.41 and a 200-day moving average of $90.90. Masimo Corporation has a 1-year low of $53.78 and a 1-year high of $104.71. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of 13.83 and a beta of 0.80.
Masimo Corporation (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.12. The business had revenue of $192.90 million during the quarter, compared to the consensus estimate of $189.03 million. Masimo Corporation had a net margin of 45.90% and a return on equity of 23.45%. Masimo Corporation’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.57 earnings per share. Analysts predict that Masimo Corporation will post $2.80 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/masimo-corporation-masi-shares-sold-by-first-trust-advisors-lp/1535311.html.
A number of brokerages recently weighed in on MASI. BidaskClub cut shares of Masimo Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. BTIG Research upgraded shares of Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $108.00 target price (up from $105.00) on shares of Masimo Corporation in a report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Masimo Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, Wedbush restated an “outperform” rating and set a $112.00 target price on shares of Masimo Corporation in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $95.00.
In related news, Director Sanford Fitch sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $91.89, for a total transaction of $551,340.00. Following the completion of the sale, the director now directly owns 89,249 shares of the company’s stock, valued at $8,201,090.61. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Anand Sampath sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $92.00, for a total transaction of $3,680,000.00. Following the sale, the chief operating officer now directly owns 20,000 shares of the company’s stock, valued at $1,840,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 126,000 shares of company stock valued at $11,732,930. 16.60% of the stock is currently owned by insiders.
About Masimo Corporation
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.